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ABSTRACT
In vertebrates, homologous recombinational repair
(HRR) requires RAD51 and five RAD51 paralogs
(XRCC2, XRCC3, RAD51B, RAD51C and RAD51D)
that all contain conserved Walker A and B ATPase
motifs. In human RAD51D we examined the require-
ment for these motifs in interactions with XRCC2 and
RAD51C, and for survival of cells in response to DNA
interstrand crosslinks (ICLs). Ectopic expression of
wild-type human RAD51D or mutants having a non-
functional A or B motif was used to test for comple-
mentation of a rad51d knockout hamster CHO cell
line. Although A-motif mutants complement very effi-
ciently,B-motifmutantsdonot.Consistentwiththese
results, experiments using the yeast two- and three-
hybrid systems show that the interactions between
RAD51D and its XRCC2 and RAD51C partners also
require a functional RAD51D B motif, but not motif
A. Similarly, hamster Xrcc2 is unable to bind to the
non-complementinghumanRAD51DB-motifmutants
in co-immunoprecipitation assays. We conclude that
a functional Walker B motif, but not A motif, is neces-
sary for RAD51D’s interactions with other paralogs
and for efficient HRR. We present a model in which
ATPasesitesareformedinabipartitemannerbetween
RAD51D and other RAD51 paralogs.
INTRODUCTION
DNA double-strand breaks (DSBs) represent a severe form of
DNA damage that can lead to mutations and cell death if
repaired incorrectly. Cells have evolved multiple mechanisms
to repair DSBs, including the high ﬁdelity process of
homologous recombinational repair (HRR) (1,2), which con-
tributes signiﬁcantly to the repair of DSBs in cycling cells
(3), such as those generated at the replication fork during
interstrand crosslink (ICL) removal. In vertebrates, HRR is
highly conserved and mediated by the bacterial RecA
ortholog, the Rad51 recombinase and ﬁve Rad51 paralogs
(XRCC2, XRCC3, Rad51B, Rad51C and Rad51D). Though
the biochemical functions of these paralogs in HRR are not
well understood, they have been proposed to function in early
steps (4–7) and in late steps (7–11) of recombination. The
Rad51 paralogs are necessary for cellular resistance to DSBs
(12,13), have no functional redundancy (14) and share limited
sequence homology with Rad51 and with each other [ 20%
identity; reviewed in (15)]. The regions of highest sequence
homology are the putative ATP-binding domains: the
conserved Walker A and Walker B motifs (12,13,15,16).
In human cells, several RAD51 paralog complexes have
been identiﬁed, among them the RAD51B-RAD51C-
RAD51D-XRCC2 heterotetramer, and three heterodimers:
RAD51B-RAD51C, RAD51D-XRCC2 and RAD51C-XRCC3
(4,17–24). The RAD51B-RAD51C and RAD51D-XRCC2
complexes were shown to bind to single- and double-stranded
DNA and to hydrolyze ATP, an activity enhanced by DNA
binding (4,19,25,26). The heterotetramer also exhibited
ATPase activity and preferentially bound to Y-shaped DNA
and synthetic Holliday junctions (27).
The Walker ATPase domain (28) consists of two separate
motifs, A and B, crucial components of the nucleotide-
binding site. The lysine residue in the GKT/S box of the
Walker A motif is essential for ATP-binding and contacts
the g-phosphate of the nucleotide (29). The highly conserved
aspartate/glutamate of the Walker B motif forms hydrogen
bonds with the threonine/serine of the GKT/S box and with
a bound water molecule (30) and facilitates nucleotide
hydrolysis.
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K133A substitution in the Walker A motif did not rescue
the Rad51-deﬁcient lethality of chicken DT40 cells while
the conservative (ATP binding, but no hydrolysis) K133R
substitution only gave a partially defective phenotype (31).
In in vitro assays, human RAD51-K133R showed an
increased stability of presynaptic ﬁlament formation and
enhanced homologous pairing activity compared to the
wild-type protein (32), but in a dominant-negative approach,
expression of human RAD51-K133R in a mouse embryonic
stem cell line speciﬁcally inhibited homology-directed DSB
repair (33). In the Walker B motif of human RAD51, muta-
tion in the highly conserved aspartate (D222A), but not
V221A or S223A, was shown to eliminate protein function
in the DT40 system (31). For the human RAD51 paralogs,
mutations within the Walker A motif of RAD51C and
XRCC3 were shown to greatly reduce cellular resistance to
ICLs (34,35), but mutation in the Walker A motif in
XRCC2 had little effect on complementing ability (36). Sub-
stitution of the conserved aspartate residue in the Walker B
motif of human XRCC3 (D213N) resulted in increased spon-
taneous apoptosis and complete loss of gene-complementing
activity for cell survival to ICL damage in the CHO xrcc3
mutant (37,38). Evidence suggests that nucleotide binding
and hydrolysis play important roles in the formation of
RAD51 paralog complexes. For example, in XRCC3, the
inability to hydrolyze bound ATP (i.e. a Walker A GRT sub-
stitution) blocks the interaction with RAD51C (35). A study
of the paralog interactions of mouse Rad51D Walker
A mutants has also been reported (39), and these results are
discussed later.
In this study, Walker-motif mutants of RAD51D were
tested for their ability to complement the MMC sensitivity
of CHO rad51d knockout cells [hereafter written as rad51d
cells; (2)]. Surprisingly, RAD51D mutants of the GKT box
of the Walker A motif rescued the MMC sensitivity of
RAD51D cells, whereas B-motif mutants did not comple-
ment. In addition, whereas A-motif mutations had little effect
on the interaction of rad51d with binding partners XRCC2
and RAD51C, mutations in the B-motif disrupted these inter-
actions. These results constitute the novel ﬁnding of a differ-
ential requirement for the Walker A and B motifs of a human
ATPase.
MATERIALS AND METHODS
Cell culture
Parental CHO cells (strain AA8) and 51D1Lox and 51D1
(rad51d) derivatives (2) were grown in monolayer or suspen-
sion cultures in MEM-alpha medium supplemented with 10%
fetal bovine serum, 100 mg/ml streptomycin and 100 U/ml
penicillin. For the experiments involving chronic MMC expo-
sures and the generation of denatured and crude protein
lysates from rad51d derivatives, cells were grown under
selection in 700 mg/ml hygromycin B.
Human RAD51D expression plasmids
The RAD51D cDNA was PCR ampliﬁed from plasmid
pDS200 (40) and subcloned into pcDNA3.1/hygro
(Invitrogen) from HindIII to NheI. The entire RAD51D
open reading frame (ORF) was veriﬁed by direct sequenc-
ing. Mutations were introduced using the QuickChange
Site-directed mutagenesis II kit (Stratagene), and missense
mutations were conﬁrmed by direct sequencing of the
entire ORF. Mutagenic primers were designed to create
the following changes to the amino acid sequence
of RAD51D: K113R, 50-GGCCCAGGTAGCGGCCGC-
ACTCAGGTATGTCTCTGTATGGC-30; K113A, 50-GG-
CCCAGGTAGCGGCGCTACTCAGGTATGTCTCTGTAT-
GGC-30; V203E, 50-GGAACTGTGAAGGTGGAGGTTG-
TGGACTCGGTCACTGCGG-30; and D206A, 50-GGAACT-
GTGAAGGTGGTGGTTGTGGCTTCGGTCACTGCGG-30
(only forward primers are shown; reverse primers had the
complementary sequence).
Yeast two- and three-hybrid system
The yeast strain Y190-ura
  (40) was used for all yeast two-
and three-hybrid experiments. For yeast two-hybrid analyses,
Y190-ura
  was co-transformed with both a DNA-binding
domain [pGBT9; (41)] and a transcription-activating domain
fusion plasmid [pGAD424; (41)] and transformants were
recovered on selective media (i.e. synthetic complete media
lacking leucine and tryptophan: SC  Leu,  Trp). For yeast
three-hybrid analyses, RAD51B was expressed from
pVT100U, a yeast expression vector containing the URA3
selectable marker (42) as described in (40). To test three-
hybrid interactions, strains containing two plasmids, grown
in SC  Leu,  Ura, were transformed with the third plasmid,
derived from pGBT9, and selected on plates lacking leucine,
tryptophan and uracil. Four independent colonies for all trans-
formations were assayed qualitatively for b-galactosidase
activity using X-gal ﬁlter assay (43). To quantify the strength
of protein–protein interactions, liquid b-galactosidase assays
were performed using o-nitrophenyl-b-galactopyranoside
(Sigma) as a substrate as described (43). All quantitative
b-galactosidase activity assays were performed on three to
ﬁve independent colonies, each monitored in triplicate. Stan-
dard error of the mean (SEM) was determined among inde-
pendent colonies. Yeast two-hybrid plasmids for RAD51D,
XRCC2 and RAD51C are described in (40). Mutations were
introduced into the RAD51D using site-directed mutagenesis
and mutagenic primers as described above. Mutations were
introduced into the XRCC2 ORF using the QuickChange
site-directed mutagenesis II kit (Stratagene). Missense
mutations were conﬁrmed by direct sequencing of the entire
ORF. Mutagenic primers for XRCC2 were designed as
follows: K54R, 50-GGCCCAGAAGGAACAGGACGCAC-
AGAAATGC-30; K54A, 50-GGCCCAGAAGGAACAGGA-
GCTACAGAAATGC-30; D149A, 50-GCCTTTTGATTT-
TGGCCAGCCTGTCAGCTTTTTACTGG-30; L148S, 50-GC-
CTTTTGATTTCAGATAGCCTGTCAGCTTTTTACTGG-30;
(only forward primers are shown; reverse primers had the
complementary sequence).
Whole cell protein extracts from transformed yeast
strain Y190U-ura
To monitor the expression levels of Gal4-RAD51D in
Y190U-ura
  transformants, whole cell protein extracts were
generated according to published procedures (44). Western
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ﬁlters were probed with 1:2000 diluted primary anti-
RAD51D (Novus Biologicals). The signal for actin (dilution
1:300; Santa Cruz Biotech) was used as a loading control.
Detection was carried out using horseradish peroxidase
(HRP)-conjugated goat anti-rabbit secondary antibody (Jack-
son ImmunoResearch; 0.4 mg/ml). Filters were incubated
with Supersignal WestPico substrate kit (Pierce Chemical)
followed by exposure to Hyperﬁlm ECL (Amersham
Biosciences).
Expression and purification of recombinant RAD51D
and XRCC2 by affinity chromatography
For recombinant expression of GST-XRCC2 and His6-
RAD51D, respective cDNAs were inserted into the bac-
ulovirus transfer vector pFASTBAC  DUAL (Invitrogen).
The glutathione S-transferase (GST) ORF ﬂanked by a
PreScission Protease cleavage site was inserted upstream
and in frame with the XRCC2 ORF. For PCR ampliﬁcation
of the RAD51D cDNA an N-terminal His6-tag was built in
the forward primer. Proteins were expressed in Sf9 insect
cells and puriﬁed to 80% homogeneity. One L of insect cell
culture was harvested at 72 h post-infection, and cells were
pelleted at 1600 g (Sorvall GSA rotor) and resuspended in
20 ml of cell lysis buffer [20 mM HEPES (pH 8.0),
100 mM NaCl, 10% glycerol, 0.5 mM phenylmethylsul-
fonylﬂuoride (PMSF), 5 mg/ml aprotinin and 5 mg/ml
leupeptin]. The cell suspension was incubated on ice for
20 min, sonicated and clariﬁed by ultracentrifugation at
110000 g (Beckman 70.1 Ti rotor) for 20 min. The supernat-
ant was applied to a 5 ml Glutathione Sepharose 4 FF column
(Amersham Biosciences) equilibrated with 10 column
volumes buffer A [1 · phosphate buffered saline (PBS),
10% glycerol]. Bound GST-XRCC2:His6-RAD51D complex
was washed with 10 column volumes buffer A and eluted
with buffer B [10 mM glutathione, 50 mM Tris–HCl
(pH 8.0), 10% glycerol]. Peak fractions were pooled and dia-
lyzed into PreScission Protease cleavage buffer [50 mM Tris–
HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA, 10% glycerol,
1 mM DTT, 0.5 mM PMSF, 5 mg/ml aprotinin and 5 mg/ml
leupeptin] for subsequent cleavage by PreScission Protease
according to the manufacturer’s description (Amersham
Biosciences). Following cleavage, the protein was diluted
1:1 with 100% glycerol and stored at  80 C.
Transfection of rad51d cells
Transfectants of rad51d cells (2) that stably express wild-type
or mutant human RAD51D protein were created by electro-
poration (625 V/cm, 950 mF) using Gene Pulser II (Bio-Rad).
A total of 1 · 10
6 cells were electroporated in 400 ml cytomix
buffer using 10 mg of linearized plasmid (45). Twenty-four
hours post-transfection, cells were plated into 10 cm dishes
at  10
4 cells/dish in 20 ml of medium containing hygro-
mycin B (700 mg/ml) and incubated for 12 days for colony
formation. Ten colonies were isolated and expanded for
each transfected plasmid and analyzed for expression of the
transgene by western blot analysis (22). Filters were probed
with 1:2000 diluted primary anti-RAD51D (Novus Biologi-
cals). The signal for the transcription factor QM (dilution
1:10000; Santa Cruz Biotech) was used as a loading
control. Detection was carried out using HRP-conjugated
goat anti-rabbit secondary antibody (Jackson Immuno-
Research; 0.4 mg/ml). Filters were incubated with Super-
signal WestPico substrate kit (Pierce Chemical) followed by
exposure to Hyperﬁlm ECL (Amersham Biosciences).
Genetic complementation analysis
MMC sensitivity was determined by colony formation assay
in 10 cm dishes. Exposure to MMC (Sigma) was conducted in
10 ml suspension cultures. For each dose, 1 · 10
6 cells were
exposed to MMC for 60 min at 37 C, centrifuged and resus-
pended in fresh medium for plating. For each dose, 300 or
more cells were plated in triplicate. After 12 days of growth,
dishes were rinsed with saline, ﬁxed with 95% ethanol and
stained with Gram Crystal Violet. Colonies with >50 cells
were scored.
To test for complementation directly in transfected cell
populations, transfections were carried out as described
above. Twenty-four hours post-transfection, cells were trypsi-
nized and re-seeded at 4 · 10
4 cells/well in 6-well plates in
regular growth medium containing hygromycin B without
MMC, or with MMC at various concentrations. Colonies
were ﬁxed and stained after 12 days of growth. The surviving
fraction of colonies was calculated as the ratio of the number
of colonies in selection in MMC and hygromycin B to the
number of colonies in the presence of hygromycin B only.
For comparison purposes, untransfected AA8 were plated at
200 cells/well in regular growth medium lacking hygromycin
B, both with and without MMC. In addition, rad51d cells
were transfected with the empty vector control (pcDNA3.1/
hygro) and plated at 4 · 10
4 cells/well in regular growth
medium containing hygromycin B without or with MMC.
The transfection efﬁciencies for all plasmids used were deter-
mined in a separate experiment. Plasmids were electroporated
as described above and cells were plated 24 h post transfec-
tion in regular growth medium containing hygromycin B. The
stable transfection efﬁciencies were found to be similar for all
plasmids used and were 0.27 ± 0.03%.
Immunoprecipitation
Immunoprecipitation was performed as described previously
(22) using native cellular protein extracts from untransfected
rad51d and AA8 cells and rad51d cells stably expressing
either wild-type or mutant RAD51D. Immunoprecipitation
was carried out using MagnaBind goat anti-rabbit IgG mag-
netic beads (Pierce) and anti-RAD51D antibody (Novus Bio-
logicals) or control antibody (rabbit IgG, Santa Cruz
Biotech). The polyclonal rabbit anti-human XRCC2 antibody
for direct immunoprecipitation of hamster Xrcc2 was kindly
provided by Dr P. Sung. Western blots were probed with
1:2000 diluted primary anti-RAD51D and 1:1000 diluted
primary anti-XRCC2 antibody (Santa Cruz Biotech). Detec-
tion was carried out using HRP-conjugated goat anti-rabbit
secondary antibody (see above) or bovine anti-goat secondary
antibody (1:10 000; Santa Cruz Biotech). Filters were incu-
bated as described above for analysis of RAD51D-expressing
rad51d cells. To visualize co-immunoprecipitated hamster
Xrcc2, ﬁlters were incubated with ECL-Advance (Amersham
Biosciences).
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Complementation of rad51d cells by ectopic expression
of wild-type human RAD51D
Following transfection of rad51d cells [clone 51D1; (2)]
with the wild-type RAD51D expression construct, colonies
were selected for hygromycin resistance. To test whether
these clones stably expressed the human cDNA, we picked
10 independent colonies and expanded them to mass cul-
tures for western blot analysis. As shown in Figure 1A,
seven of these clones stably expressed the transgene. Since
the expression levels for RAD51D protein varied, one clone
expressing a lower level of the protein (WT1; WT for wild-
type) and one expressing a higher level (WT2) were selected
to test whether ectopic expression of human RAD51D res-
cued the very high ( 80-fold) MMC sensitivity of rad51d
cells (2). Using the colony formation assay for cell survival,
we found that both clones WT2 and WT1 were efﬁciently
complemented; their MMC resistance was similar to that
of the wild-type AA8 cells (Figure 2A and B, respectively).
We also observed that the parent of 51D1, 51D1Lox,
which contains functional Rad51D alleles prior to Cre-
recombinase treatment (2), was slightly more sensitive to
MMC ( 2-fold; determined from D37 values) than AA8
cells or rad51d cells expressing wild-type human
RAD51D (Figure 2A and B). We explain this observation
in part by the fact that the endogenous hamster Rad51D
protein level in AA8 cells (and possibly the human protein
in clones WT1 and WT2) is higher than in 51D1Lox cells
(2). However, due to interspecies variation in antibody
recognition it is not possible for us to compare the protein
levels in 51D1Lox cells (i.e. hamster Rad51D) to that in
the transfectants (i.e. human RAD51D).
Complementation of rad51d cells by ectopic expression
of RAD51D Walker A-motif ATPase mutants
We tested whether a conservative amino acid substitution
(K113R; binds but does not hydrolyze ATP), or a non-
conservative substitution (K113A; unable to bind ATP), in
the GKT box of the Walker motif A inﬂuenced the ability
of RAD51D to complement the rad51d mutant. We trans-
fected rad51d cells with each mutant construct (GRT and
GAT; see Figure 1E) and isolated 10 independent clones
for each mutant. As shown in Figure 1B and C by western
blot analysis, the protein expression levels of independent
clones stably expressing either mutant of RAD51D varied.
As with the cells expressing the wild-type RAD51D con-
struct, for each mutant we choose a low-expressing clone
(GAT2 and GRT3 (GRT2 was added in follow-up experi-
ments); see Figure 1C and B, respectively), and a high
expressing clone (GRT6 and GAT4; see Figure 1B and C,
respectively). We found that stable expression of either mut-
ant protein largely complemented MMC sensitivity of rad51d
cells (Figure 2A and B). The degree of MMC resistance of
the high-expressing lines (GRT6 and GAT4) was similar to
that of AA8 cells and rad51d cells expressing wild-type
RAD51D (WT2) (Figure 2A). For the low-expressing lines
(GRT2, GRT3 and GAT2), complementation was less com-
plete [ 2- to 3-fold lower, as determined from the D37 values
(Figure 2B)]. However, these lower expressing lines were
clearly no more sensitive to MMC than parental 51D1Lox
cells that express reduced levels of hamster Rad51D
[Figure 2B; (2)].
Figure 1. Representative western blots showing the expression levels for
wild-type human RAD51D and its mutant forms in clonal isolates of stably
transfected hamster rad51d cells. (A) rad51d clones expressing wild-type
human RAD51D, Upper panel: anti-RAD51D antibody; lower panel:
anti-QM antibody (loading control). Extract from untransfected rad51d cells
is in left lanes of (A–D). (B) rad51d clones expressing RAD51D-K113R
(GRT1-GRT6) or RAD51D-K113A (GAT5 and GAT6; loaded for compari-
son); lower panel as in (A). (C) rad51d clones expressing RAD51D-K113A
(GAT2-GAT5)orwild-typeRAD51D(WT2;loadedforcomparisonpurposes);
lower panel as in (A). (D) rad51d clones expressing RAD51D-D206A or
RAD51D-V203E.ExtractofcloneWT2(expressingwild-typeRAD51D)mon-
itored for comparison purposes; lower panel as in (A). The asterisk indicates
thatV203Erunswithslightlyslowermobility.‘WB’indicatesantibodyusedin
western blot analysis. ‘WB’ indicates antibody used in western blot analysis
(A–D).(E)DomainstructureoftheRAD51Dproteinillustratingtheaminoacid
substitutions introduced into the RAD51D cDNA. (A): Walker A motif; (B):
Walker B motif. Highly conserved residues are underlined in the wild-type
sequence. Amino acid substitutions introduced are bold italics. Numbers in-
dicate residue location within the primary sequence of RAD51D.
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expressionofRAD51DWalkerB-motifATPasemutants
Since we observed almost no abnormality in cellular pheno-
type for the Walker A-motif mutations, we hypothesized that
the Walker B motif may predominately determine the func-
tion of RAD51D. To test this possibility, we mutated the
highly conserved aspartate (D206) to alanine (D206A; see
Figure 1E). For comparison purposes, we also made the pre-
viously uncharacterized V203E substitution within motif B of
RAD51D. This valine was chosen for mutagenesis as it is
conserved among the human RAD51 paralogs RAD51B,
RAD51C, RAD51D and XRCC3, and in mouse and hamster
Rad51D. Both expression constructs (V203E and D206A)
were separately transfected into rad51d cells, and cells
were selected in the continuous presence of either
hygromycin alone or hygromycin plus increasing concentra-
tions of MMC. The extent of complementation for expression
of all RAD51D constructs was assessed by comparing the
number of colonies arising in hygromycin and MMC to the
number of colonies arising in hygromycin alone. As shown
in Figure 2C, ectopic expression of either RAD51D-V203E
or RAD51D-D206A does not result in complementation of
MMC sensitivity of rad51d cells measured by colony forma-
tion. Conversely, in this same method of analysis, expression
of wild-type RAD51D, or the Walker A box mutants
RAD51D-K113R and RAD51D-K113A resulted in high
MMC resistance (Figure 2C) albeit expression of either
K113R or K113A did not fully protect against killing.
Whether these latter modest reductions are biochemically sig-
niﬁcant is unclear since the expression levels of the A-motif
mutant proteins could be slightly lower than that of wild-type.
As with the A-motif mutants, both B-motif mutants are
expressed stably in rad51d cells (Figure 1D).
Inability of RAD51D Walker B mutants to interact with
XRCC2 in the yeast two-hybrid system
As RAD51D B-motif mutants are unable to repair MMC-
induced DNA damage, we investigated whether disruptions
occur in the interactions between RAD51D and its known
paralog partners. To do so, we employed the yeast two- and
three-hybrid systems and tested whether mutant RAD51D
would be able to interact with either XRCC2 or RAD51C.
Each of the described forms of RAD51D (wild-type,
K113R, K113A, V203E and D206A) was generated by site-
directed mutagenesis using previously described vectors
carrying wild-type RAD51D (40). First, each RAD51D
protein was tested for binding to wild-type XRCC2 in
both orientations (Figure 3A). The average strength of the
RAD51D-K113R:XRCC2 interactions was 75 or 57% of
the wild-type RAD51D:XRCC2 interaction (dependent on the
orientation of the Gal4-fusion), and the average strength of
Figure 2. Cell survival determined by colony formation assay after acute or
chronicexposuretoMMC.(A)Parentallinesandhigh-expressingtransfectants
carrying Walker A-motif mutations were exposed to MMC for 60 min. AA8,
solid squares; 51D1Lox (Rad51d+), open squares; 51D1 (rad51d) expressing
wild-type human RAD51D (WT2), half-filled squares; 51D1 expressing
WalkerA-motifmutant,cloneGAT4,soliddiamonds;51D1expressingWalker
A-motif mutant, clone GRT6, solid circles. (B) Parental, mutant (clone: 51D1)
and low-expressing transfectants carrying Walker A-motif mutations were
exposed to MMC for 60 min. Mutant 51D1 (rad51d), open diamonds; 51D1
expressingWalkerA-motifmutant,clone GAT2,soliddiamonds;51D1 expre-
ssing Walker A-motif mutant, clone GRT2, solid triangle; 51D1 expressing
WalkerA-motifmutant,cloneGRT3,solidcircle;forAA8,51D1Loxand51D1
expressing wild-type RAD51D (here clone WT1) symbols same as in (A).
Horizontal line indicates D37 survival. (C) Survival of colony-forming ability
in response to continuous MMC exposure of rad51d cells and transfectants
expressing either wild-type RAD51D (WT; open squares), K113R (open
triangles, K113A (open circles), V203E (open diamonds), D206A (closed
triangles). AA8 cells (closed circles) and rad51d cells transfected with
the empty vector (pcDNA3.1/hygro; black cross) are shown for comparison.
Error bars that are visible are ± 1 standard deviation from three independent
experiments.
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wild-type levels (100 and 90%, depending on the orientation
tested; see Figure 3A).
Strikingly, both B-motif mutants displayed greatly reduced
interaction with XRCC2 in either fusion orientation
(Figure 3A). The average strength of the RAD51D-V203E:
XRCC2 interactions was determined to be at 1 and 3% of
the wild-type interaction, and the average strength of the
RAD51D-D206A:XRCC2 interactions was at 3 and 11% of
the wild-type interaction (depending on the orientation
tested). To ensure that the RAD51D mutants are produced
in amounts adequate to detect positive protein interactions
in the yeast two-hybrid system, we tested the protein expres-
sion levels for Gal4-RAD51D and its mutant forms by
immunoblotting of total protein extracts (Figure 3C). As for
the wild-type, all mutant forms of the Gal-RAD51D fusions
were produced at high levels in yeast. Although K113R,
V203E and D206A were repeatedly expressed at slightly
lower levels than the wild-type and K113A, the failure of
XRCC2 to interact with V203E and D206A is not due to
the unavailability of these mutant proteins in yeast. For exam-
ple, even though K113R and V203E are expressed at similar
levels, they differ greatly in their ability to interact with
XRCC2 (see Figure 3A and 3C).
Inability of RAD51D Walker B mutants to interact with
RAD51C in the yeast three-hybrid system
The interaction between human RAD51D and RAD51C,
when tested in the yeast two-hybrid system, is comparatively
weak, making it difﬁcult to quantitatively assess protein–
protein interactions that potentially are reduced even further.
However, co-expression of RAD51B, in a non-fused form,
has been shown previously to greatly enhance the strength
of the RAD51D:RAD51C interaction in a yeast three-hybrid
system (40). Furthermore, in vivo a stable RAD51D-RAD51C
heterodimer has not been discovered, whereas RAD51D and
RAD51C were shown to be part of the heterotetramer that
also contains RAD51B and XRCC2 (20–22,24). For these
reasons, we used the yeast three-hybrid system to assess the
ability of either wild-type or mutant RAD51D to interact with
RAD51C when RAD51B is co-expressed. We found that the
average strength of interactions between Walker A K113R
and RAD51C was reduced to 60% of the wild-type level,
and the average strength of interactions between Walker
A K113A and RAD51C was at 67% of the wild-type interac-
tion (Figure 3B). Notably, the interactions between RAD51D
Walker B mutants and RAD51C were virtually eliminated,
not differing from the negative control (Figure 3B).
No co-immunoprecipitation of RAD51D Walker B
mutants with hamster Xrcc2
To investigate in vivo complex formation between wild-type
or mutant human RAD51D and hamster Xrcc2, we performed
reciprocal co-immunoprecipitation in extracts from rad51d
clones that stably express the ectopic proteins at similar
levels. We found that hamster Xrcc2 is present speciﬁcally
in anti-RAD51D immunoprecipitated complexes from
clone WT2 (which overexpresses wild-type RAD51D) and
not immunoprecipitated using IgG control antibody
(Figure 4A). In addition, CHO cells appear to express
two isoforms of Xrcc2 (as indicated by the double arrows
in Figure 4A–C) that both bind to RAD51D. The faster
migrating isoform displays the same mobility as recombinant
human XRCC2 (Figure 4C), while the second isoform
appears to be larger and migrates with a shift that corresponds
to a 2–3 kD difference in molecular weight. It is likely, but
not clear yet, that this larger form of hamster Xrcc2 may be
a modiﬁed version of the protein. We also have observed both
isoforms of Xrcc2 in V79 hamster cells but not in mouse
mammary epithelial cells (data not shown). Importantly,
Xrcc2 was present in anti-RAD51D immunoprecipitated
Figure 3. Yeasttwo-andthree-hybridanalysesoftheinteractionsofwild-type
or mutant RAD51D with XRCC2 or the RAD51C:RAD51B heterodimer,
respectively. (A) Quantitative assessment of the RAD51D:XRCC2 inter-
action: b-galactosidase units determined photospectrometrically by using
o-nitrophenyl-b-galactopyranoside as a substrate (1 U corresponds to
DOD420 nm/min/mg protein). (B) Quantitative assessment of the RAD51D:
RAD51B:RAD51C interaction: b-galactosidase units determined as in (A).
Results in (A and B) are from three to five different colonies for every inter-
action, each assayed in triplicate. Error bars represent ± 1 SEM; error bars that
are not visible are too small to display. DBD ¼ DNA binding domain of Gal4;
AD ¼ transactivating domain of Gal4; NF ¼ non-fused protein (here:
RAD51B). (C) Western blot to monitor the expression of Gal4AD-RAD51D
wild-typeandmutantformsinyeastY190U-ura
 transformants.Threecolonies
for each transformation were tested, and a representative blot is shown.
Upper panel, anti-RAD51D antibody; lower panel, anti-actin antibody loading
control.
2838 Nucleic Acids Research, 2006, Vol. 34, No. 9complexes from rad51d cells overexpressing A-motif
mutants (K113R and K113A), but absent in anti-RAD51D
immunoprecipitated complexes from B-motif mutants
(D206A and V203E; Figure 4B). Although reproducibly at
lower levels compared to the wild-type expressing line
(WT2; here: GKT), Xrcc2 was always present in anti-
RAD51D immunoprecipitated complexes from clones
GAT4 and GRT6, which overexpress Walker A K113A and
K113R mutant protein, respectively. Anti-RAD51D immuno-
precipitated complexes from parental AA8 and rad51d cells
contained neither RAD51D nor Xrcc2, demonstrating the
inability of the anti-RAD51D antibody to recognize the ham-
ster Rad51D protein in AA8 cells and the absence of human
RAD51D in rad51d cells.
In reciprocal experiments we analyzed anti-Xrcc2
immunoprecipitated complexes from all cell lines for the
presence of RAD51D (Figure 4C). We found that the
amounts of endogenous Xrcc2 directly precipitated by anti-
XRCC2 antibody varied greatly among all cell lines tested
(even though their expression levels for ectopic RAD51D
were comparable; see Figure 1). Only small amounts of
Xrcc2 were precipitated from extracts of rad51d cells and
rad51d cells expressing Walker B-motif mutants D206A or
V203E (Figure 4C). Signiﬁcantly larger amounts of Xrcc2
were precipitated from cells overexpressing wild-type
RAD51D, K113R or K113A and from AA8 cells.
(Note: for AA8 cells only 1/16 of the amount of the precipi-
tated complex was loaded onto the gel, relative to all other
cell lines). We reproducibly detected wild-type RAD51D
(here: GKT), K113R and K113A in anti-Xrcc2 immunopre-
cipitated complexes (Figure 4C, lower panel). Not surpris-
ingly, only small amounts of Walker B mutant proteins
were present in anti-Xrcc2 complexes from rad51d cells
overexpressing either V203E or D206A (Figure 4C). In
sum, these results show that ectopically expressed wild-type
RAD51D, or RAD51D with mutations in the Walker
A motif, formed a stable complex with hamster Xrcc2.
Conversely, motif-B mutants, although expressed at similar
levels, had reduced levels of hamster Xrcc2, probably due
to the inability to stabilize this protein as a RAD51D-Xrcc2
heterodimer (Figure 5C; see Discussion).
Greatly impaired interaction of XRCC2-K54A and
RAD51D in the yeast two-hybrid system
As we observed little decrease in interaction between
RAD51D A-motif mutants and Xrcc2/XRCC2 both in vivo
and in the yeast two-hybrid system, we hypothesized that
XRCC2’s Walker A motif participates in nucleotide-binding
within the XRCC2-RAD51D heterodimer. Interestingly, a
Figure 4. RAD51Dwild-typeandmotif-AmutantsallowcomplexformationwithhamsterXrcc2invivo.(A)CrudeextractfromcloneWT2(overexpressingwild-
type human RAD51D) immunoprecipitated with a polyclonal antibody against RAD51D. Precipitated RAD51D (upper panel) and co-precipitated Xrcc2 (lower
panel)weredetectedbywesternblotanalysisonthesamemembrane.AmockimmunoprecipitatebyincubationofWT2extractswithIgGcontrolantibodyisshown
in the far left lane. For comparison purposes, whole cell extract from clone WT2 is shown in the far right lane. Note: Xrcc2 is present in two isoforms in CHO cells
[strain AA8 and derivatives; see also (C)]. ‘HC’ indicates cross-reacting heavy chain signal. ‘IP’ indicates antibody used for immunoprecipitation. ‘WB’ indicates
antibodyusedinwesternblot.(B)PresenceofXrcc2inanti-RAD51DimmunoprecipitatedcomplexesfromclonesWT2(GKT),GRT6(K113R)andGAT4(K113A).
Xrcc2 is not present in anti-RAD51D complexes from parental AA8 or rad51d cells (neither cell line expresses human RAD51D that is precipitated here).
Forcomparison,crudeextractsfromhumancells(HeLa;farleftlane),WT2cells(GKT;secondlanefromtheright),andAA8cells(farrightlane)areshown.Upper
and lower panels: western blot probed with Rad51D and XRCC2 antibodies, respectively. (C) Endogenous hamster Xrcc2 is expressed at higher levels in cell lines
expressingcomplementingRAD51D(GKT,K113R,K113A)thatisabletointeractwithXrcc2.Upperpanel:westernblotprobedwithanti-XRCC2antibodyshows
twoXrcc2isoformsinXrcc2immunoprecipitatedcomplexesfromrad51d,K113R,K113A,D206A,V203EandGKTcelllines.PrecipitatedXrcc2fromAA8cellsis
shownforcomparison(farleftlane;notethatonly1/16oftheprecipitatedcomplexrelativetoallothercelllineswasloadedinordertoavoidaverystrongsignalfor
Xrcc2). Two different concentrations of recombinant human XRCC2/(His)6-RAD51D complex isolated from insect cells (second and third lanes from the left) and
crude extract from clone WT2 (GKT; far right lane) are included. Lower panel: same blot probed with RAD51D antibody to detect human RAD51D that co-
immunoprecipitated with hamster Xrcc2. Note: recombinant human His6-tagged RAD51D migrated more slowly than human RAD51D.
Nucleic Acids Research, 2006, Vol. 34, No. 9 2839newly identiﬁed Rad51 paralog in Schizosaccharomyces
pombe, Rlp1, having homology to human XRCC2 shows a
conserved Walker A motif but no clearly deﬁned Walker B
motif (46). Therefore, we made the conservative K54R and
non-conservative K54A substitutions in the Walker A motif
of XRCC2, using previously described yeast two-hybrid plas-
mids (40), and assayed their interaction with wild-type
RAD51D, RAD51D-K113R or RAD51D-K113A qualita-
tively and in both orientations by X-Gal ﬁlter assay
(Figure 5A and B, respectively). XRCC2-K54A was greatly
impaired in binding to wild-type RAD51D and mutant
RAD51D (Figure 5A and B, respectively; light blue and
white colonies). However, XRCC2-K54R was able to interact
with wild-type RAD51D and both motif-A mutants of
RAD51D (Figure 5A and B, respectively). In addition, we
introduced L148S or D149A amino acid substitutions within
the Walker B motif of XRCC2 and assessed whether these
XRCC2 mutants could interact with wild-type RAD51D in
the yeast two-hybrid system. Both XRCC2-L148S and
XRCC2-D149A were impaired in binding to wild-type
RAD51D, although B-motif mutants of XRCC2 appeared to
be less detrimental to the XRCC2:RAD51D interaction than
B-motif mutants of RAD51D (Figure 5C; see Discussion).
DISCUSSION
To our knowledge we have described the ﬁrst human ATPase
with disparate requirements for two highly conserved Walker
A/B motifs, both of which are generally crucial components
of the nucleotide-binding site. Because of the complete loss
of RAD51D function caused by amino acid substitution
within its conserved B motif, the contrasting ﬁnding, of nor-
mal biological function for GKT substitutions within the A
motif, was quite unexpected. Moreover, a recent study of
mouse Rad51D using rad51d mouse cells, in which only
A-motif mutants were examined, reached the opposite con-
clusion, ‘that conservation of Walker Motif A is required
for a physiological role of RAD51D’ (39). Relative to the
wild-type control, these authors reported  90% decrease in
cell survival after exposure to MMC for K113R and
K113A mutants in bulk transfected cell populations. How-
ever, these investigators did not perform standard MMC
dose-response measurements to calculate the dose-reduction
factor of cell sensitivity associated with the mouse Rad51D
mutant forms. Since we also observed a slightly increased
sensitivity to MMC (calculated by dose-reduction factor)
under some conditions for both acute and chronic exposures
(Figure 2B and C), the only discrepancy between our survival
data and theirs is the extent of reduced complementation by
the A-motif mutants.
In addition, Gruver et al. (39) reported moderately
impaired interactions of mouse Rad51D A-motif mutants
with Xrcc2, but strongly impaired interactions with Rad51C
in the yeast two-hybrid system. Although we also found
greatly impaired interactions between the human RAD51D
Walker A mutants and RAD51C in yeast two-hybrid experi-
ments when monitored qualitatively (data not shown), in the
yeast three-hybrid system we found that these interactions
were only moderately affected when tested in the presence
of RAD51B. As discussed in the Results above, we believe
that the yeast three-hybrid system more closely reﬂects the
in vivo interaction context.
Similar to our ﬁnding of gross defects associated with the
B-motif D206A mutant of RAD51D, human XRCC3 substi-
tution at the corresponding aspartate (D213N) dramatically
reduced MMC resistance when expressed in hamster xrcc3
irs1SF cells (37). As suggested by others (31,37), substitution
of this highly conserved aspartate likely disrupts ATP binding
and/or hydrolysis activity. Nonetheless, XRCC3 does behave
differently from RAD51D in that both Walker motifs are
critical for XRCC3’s function (35,37).
We presented evidence that alterations in the Walker
B motif of RAD51D (V203E or D206A substitutions)
greatly impair RAD51D-XRCC2 complex formation. Co-
immunoprecipitation clearly shows that, in the presence of
Figure 5. Yeast two-hybrid analysis of the interactions between Walker A/B
mutants of XRCC2 and RAD51D. (A) Greatly impaired XRCC2-K54A inter-
action with wild-type RAD51D. Qualitative assessment: expression of
b-galactosidase by X-gal filter assay; blue patches indicate the expression of
interactingproteins;onerepresentativecolonyisshown.(B)Pairwiseanalyses
oftheinteractionbetweenWalkerAmutantsfrombothXRCC2andRAD51D.
Qualitative assessment: as in (A). (C) Comparative analysis of the interaction
between either XRCC2-L148S or XRCC2-D149A and RAD51D or between
XRCC2 and RAD51D-D206A. Results are from three different colonies
for every interaction, each assayed in triplicate. Error bars represent
±1SEM.DBD¼DNAbindingdomainofGal4;AD¼transactivatingdomain
of Gal4.
2840 Nucleic Acids Research, 2006, Vol. 34, No. 9these non-complementing RAD51D mutant proteins, there is
much less hamster Xrcc2 protein than under conditions where
complementing RAD51D (i.e. wild-type or motif-A mutants)
is available. It is important to note from these experiments that
the rad51d knockout cell line itself (i.e. untransfected) also
expresses greatly reduced levels of endogenous Xrcc2 protein
when compared to its AA8 parent line, which expresses wild-
type hamster Rad51D (Figure 4C). Our ﬁndings are consistent
with several studies showing the stabilization of RAD51
paralogs by each other in vivo (7,22,47,48), but our data addi-
tionally demonstrate that the ability to interact directly is
required for this stabilization. In addition, neither Walker
B-motif mutant is able to interact with the RAD51B:RAD51C
heterodimer in the yeast three-hybrid system.
The loss of RAD51D-XRCC2 and RAD51D-RAD51C
interactions by disruption of nucleotide binding (V203E or
D206A substitutions) raises the question of which biochemical
defect (nucleotide binding or protein–protein interaction) is
responsible for the cellular phenotype of high sensitivity to
MMC. Our preferred view is that the role of the ATPase activ-
ity that is blocked by the V203E and D206A substitutions is to
mediate a conformational change that promotes tight binding
of RAD51D with XRCC2 and/or RAD51C. In this model
ATPase site integrity and protein interaction are inseparable.
Reiterative changes in protein conformation are important
for the assembly of multi-subunit protein complexes that
function in DNA repair [for review see (49)]. Rad51 family
members induce these conformational changes, necessary to
fulﬁll protein function, by binding and hydrolysis of ATP
[for review see (30)]. X-ray crystal structures (50–54) and
electron microscopy reconstructions (53–55) of several
Rad51 homologs have provided evidence that ATP-binding
occurs at the subunit interface by contacting several highly
conserved residues on neighboring subunits. We surmise
that human RAD51D, through its Walker B motif, may rely
on the A motif of another RAD51 paralog to form an active
ATPase.
Overall, our results suggest that RAD51D must form a
complex with XRCC2 and/or RAD51C to maintain cellular
resistance to MMC. We showed that both interactions require
a normal RAD51D Walker B motif, but not an intact A motif.
We speculate that the binding of ATP to RAD51D occurs
through its Walker B box as part of a bipartite nucleotide-
binding site interacting with XRCC2 and/or RAD51C, as
illustrated in Figure 6. In Figure 6A, the B motif of
RAD51D interacts with the A motif of XRCC2. We showed
that mutations in either of these motifs block the interaction;
disruption of the XRCC2 A motif via K54A substitution (but
not K54R substitution) greatly diminishes its binding to
RAD51D in the yeast two-hybrid system (Figure 5A and
B). One published observation is inconsistent with the idea
that the RAD51D-XRCC2 interaction is important for efﬁci-
ent DNA repair. In that study, the XRCC2 A-motif K45A
mutant showed only modest decrements in MMC resistance
in irs1 V79 cells transfected with mutant proteins (36)
(although western blotting of these transfectants was not
used to standardize the expressed XRCC2 protein levels).
Moreover, in our yeast two-hybrid studies amino acid substi-
tutions within the Walker B motif of XRCC2, though clearly
affecting the XRCC2:RAD51D interaction, appear to be less
deleterious to XRCC2:RAD51D complex formation in
comparison with the RAD51D B-motif mutants
(Figure 5C). Figure 6B depicts an ATPase site composed of
the B motif of RAD51D and the A motif of RAD51C. Similar
to our results for the B motif of RAD51D, mutations in the
A motif of RAD51C also cause 80–100% loss of DNA repair
efﬁciency (34). Although RAD51D-RAD51C interactions
were not examined in that study, we found a severe RAD51-
D:RAD51C interaction defect in the yeast three-hybrid
system for the RAD51D B-motif mutants (Figure 3).
In conclusion, we provide evidence that the Walker
B motif of human RAD51D is critically important for com-
plex formation with other RAD51 paralogs and for cellular
resistance to ICLs. Since both Walker B-motif substitutions
(V203E and D206A) yielded a similar phenotype, we propose
that these substitutions not only abrogate ATP hydrolysis, but
also simultaneously prevent one or more critical interac-
tion(s) and conformational changes underlying RAD51D’s
participation in complexes, whose integrity is necessary for
recombinational repair.
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